Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial by Sharma, Padmanee, Prof, Callahan, Margaret K, MD, Bono, Petri, MD, Kim, Joseph, MD, Spiliopoulou, Pavlina, MD, Calvo, Emiliano, MD, Pillai, Rathi N, MD, Ott, Patrick A, MD, de Braud, Filippo, Prof, Morse, Michael, Prof, Le, Dung T, MD, Jaeger, Dirk, MD, Chan, Emily, MD, Harbison, Chris, PhD, Lin, Chen-Sheng, PhD, Tschaika, Marina, MD, Azrilevich, Alex, PharmD, Rosenberg, Jonathan E, MD

Get full text

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040) by Sangro, Bruno, Yau, Thomas, El‐Khoueiry, Anthony B., Kudo, Masatoshi, Shen, Yun, Tschaika, Marina, Roy, Amit, Feng, Yan, Gao, Ling, Aras, Urvi

Get full text

Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032) by Callahan, Margaret, Amin, Asim, Kaye, Frederic J, Morse, Michael A, Taylor, Matthew H, Peltola, Katriina J, Sharma, Padmanee, O'Reilly, Eileen M, Meadows Shropshire, Stephanie, O'Brien, Shaun, Tschaika, Marina, Le, Dung T

Get full text

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden by Schenker, Michael, Burotto, Mauricio, Richardet, Martin, Ciuleanu, Tudor-Eliade, Gonçalves, Anthony, Steeghs, Neeltje, Schoffski, Patrick, Ascierto, Paolo A, Maio, Michele, Lugowska, Iwona, Lupinacci, Lorena, Leary, Alexandra, Delord, Jean-Pierre, Grasselli, Julieta, Tan, David S P, Friedmann, Jennifer, Vuky, Jacqueline, Tschaika, Marina, Konduru, Somasekhar, Vemula, Sai Vikram, Slepetis, Ruta, Kollia, Georgia, Pacius, Misena, Duong, Quyen, Huang, Ning, Doshi, Parul, Baden, Jonathan, Di Nicola, Massimo

Get full text

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma by Sangro, Bruno, Melero, Ignacio, Wadhawan, Samir, Finn, Richard S., Abou-Alfa, Ghassan K., Cheng, Ann-Lii, Yau, Thomas, Furuse, Junji, Park, Joong-Won, Boyd, Zachary, Tang, Hao (Tracy), Shen, Yun, Tschaika, Marina, Neely, Jaclyn, El-Khoueiry, Anthony

Get full text

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial by Yau, Thomas, Park, Joong-Won, Finn, Richard S, Cheng, Ann-Lii, Mathurin, Philippe, Edeline, Julien, Kudo, Masatoshi, Harding, James J, Merle, Philippe, Rosmorduc, Olivier, Wyrwicz, Lucjan, Schott, Eckart, Choo, Su Pin, Kelley, Robin Kate, Sieghart, Wolfgang, Assenat, Eric, Zaucha, Renata, Furuse, Junji, Abou-Alfa, Ghassan K, El-Khoueiry, Anthony B, Melero, Ignacio, Begic, Damir, Chen, Gong, Neely, Jaclyn, Wisniewski, Tami, Tschaika, Marina, Sangro, Bruno

Get full text

CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis by Kudo, Masatoshi, Matilla, Ana, Santoro, Armando, Melero, Ignacio, Gracián, Antonio Cubillo, Acosta-Rivera, Mirelis, Choo, Su-Pin, El-Khoueiry, Anthony B., Kuromatsu, Ryoko, El-Rayes, Bassel, Numata, Kazushi, Itoh, Yoshito, Di Costanzo, Francesco, Crysler, Oxana, Reig, Maria, Shen, Yun, Neely, Jaclyn, Tschaika, Marina, Wisniewski, Tami, Sangro, Bruno

Get full text

Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment‐Related Adverse Events From the CheckMate 040 Study by Julien, Karen, Leung, Hiu Tung, Fuertes, Carmen, Mori, Megumi, Wang, Miao‐Jen, Teo, Jocelyn, Weiss, Lisa, Hamilton, Sara, DiFebo, Holly, Noh, Yoon Jin, Galway, Aralee, Koh, Jane, Brutcher, Edith, Zhao, Huanyu, Shen, Yun, Tschaika, Marina, To, Yue‐Yun

Get full text

Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040 by Sangro, Bruno, He, Aiwu Ruth, Yau, Thomas, Hsu, Chiun, Kang, Yoon-Koo, Kim, Tae-You, Santoro, Armando, Melero, Ignacio, Kudo, Masatoshi, Ho, Ming-Mo, Matilla, Ana, Tovoli, Francesco, Knox, Jennifer, El-Rayes, Bassel, Acosta, Mirelis Rivera, Neely, Jaclyn, Shen, Yun, Tschaika, Marina, El-Khoureiry, Anthony

Get full text

LBO11 - Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040 by Sangro, Bruno, He, Aiwu Ruth, Yau, Thomas, Hsu, Chiun, Kang, Yoon-Koo, Kim, Tae-You, Santoro, Armando, Melero, Ignacio, Kudo, Masatoshi, Ho, Ming-Mo, Matilla, Ana, Tovoli, Francesco, Knox, Jennifer, El-Rayes, Bassel, Acosta, Mirelis Rivera, Neely, Jaclyn, Shen, Yun, Tschaika, Marina, El-Khoureiry, Anthony

Get full text

Abstract 2145: Genomic and transcriptomic analyses related to the clinical efficacy of first-line nivolumab in advanced hepatocellular carcinoma from the phase 3 CheckMate 459 tria... by Neely, Jaclyn, Yao, Jin, Kudo, Masatoshi, Finn, Richard S., Sangro, Bruno, Melero, Ignacio, El-Khoueiry, Anthony, Tschaika, Marina, Begic, Damir, Sama, Ashwin, Doshi, Parul, Yau, Thomas, Kelley, Robin Kate

Get full text

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial by Sharma, Padmanee, Callahan, Margaret K, Bono, Petri, Kim, Joseph, Spiliopoulou, Pavlina, Calvo, Emiliano, Pillai, Rathi N, Ott, Patrick A, de Braud, Filippo, Morse, Michael, Le, Dung T, Jaeger, Dirk, Chan, Emily, Harbison, Chris, Lin, Chen-Sheng, Tschaika, Marina, Azrilevich, Alex, Rosenberg, Jonathan E

Get full text

Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic... by Schenker, Michael, Burotto, Mauricio, Richardet, Martin, Ciuleanu, Tudor, Goncalves, Anthony, Steeghs, Neeltje, Schöffski, Patrick, Ascierto, Paolo A., Maio, Michele, Lugowska, Iwona, Lupinacci, Lorena, Leary, Alexandra, Delord, Jean-Pierre, Grasselli, Julieta, Tan, David S., Friedmann, Jennifer E., Vuky, Jacqueline, Tschaika, Marina, Slepetis, Ruta, Kollia, Georgia D., Pacius, Misena, Huang, Ning, Doshi, Parul, Baden, Jonathan, Nicola, Massimo Di

Get full text

MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial by Hellmann, Matthew, Antonia, Scott, Ponce, Santiago, Ott, Patrick, Calvo, Emiliano, Taylor, Matthew, Ready, Neal, Hann, Christine, De Braud, Filippo, Eder, Joseph Paul, Jäger, Dirk, Ascierto, Paolo, Horn, Leora, Amin, Asim, Evans, Jeffry, Moreno, Victor, Atmaca, Akin, Pillai, Rathi, Bhosle, Jaishree, Bono, Petri, Reguart, Noemi, Schneider, Jeffrey, Brossart, Peter, Diamond, Jennifer, Sharma, Padmanee, Lassen, Ulrik, Lin, Chen-Sheng, Tschaika, Marina, Selvaggi, Giovanni, Spigel, David

Get full text

Abstract LB-233: Immune-related efficacy data of the phase 1-2 study of an with fourfold gene-modified allogeneic tumor cell based vaccine in patients with advanced renal cell carc... by Weith, Ekaterina, Tschaika, Marina, Weikert, Steffen, Gruenwald, Viktor, Schmidt-Wolf, Ingo GH, Hauser, Stefan, Schroff, Matthias, Kapp, Kerstin, Schmidt, Manuel, Wittig, Burghardt

Get full text

MGN1703, a Novel TLR9-Agonist - Results of a Phase 1 Clinical Trial in Patients with Metastatic Malignancies by Weihrauch, Martin R, Schmidt, Manuel, Tschaika, Marina, Richly, Heike, von Bergwelt-Baildon, Michael S, Hacker, Ulrich, Shimabokuro-Vornhagen, Alexander, Wittig, Burghardt, Scheulen, Max E

Get full text

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016 by Althammer, Sonja, Steele, Keith, Rebelatto, Marlon, Tan, Tze Heng, Wiestler, Tobias, Schmidt, Guenter, Higgs, Brandon, Li, Xia, Shi, Li, Jin, Xiaoping, Antal, Joyce, Gupta, Ashok, Ranade, Koustubh, Binning, Gerd, Bellmunt, Joaquim, de Wit, Ronald, Vaughn, David J., Fradet, Yves, Lee, Jae Lyun, Fong, Lawrence, Vogelzang, Nicholas J., Climent, Miguel A., Petrylak, Daniel P., Choueiri, Toni K., Necchi, Andrea, Gerritsen, Winald, Gurney, Howard, Quinn, David I., Culine, Stéphane, Sternberg, Cora N., Mai, Yabing, Puhlmann, Markus, Perini, Rodolfo F., Bajorin, Dean F., Sharma, Padmanee, Callahan, Margaret K., Calvo, Emiliano, Kim, Joseph W., de Braud, Filipo, Ott, Patrick A., Bono, Petri, Pillai, Rathi N., Morse, Michael, Le, Dung T., Taylor, Matthew, Spilliopoulou, Pavlina, Bendell, Johanna, Jaeger, Dirk, Chan, Emily, Antonia, Scott J., Ascierto, Paolo A., Hennicken, Delphine, Tschaika, Marina, Azrilevich, Alex, Rosenberg, Jonathan, Levy, Ofer, Chan, Christopher, Cojocaru, Gady, Liang, Spencer, Ophir, Eran, Ganguly, Sudipto, Toporik, Amir, Kotturi, Maya, Kfir, Tal Fridman, Murter, Benjamin M., Logronio, Kathryn, Dassa, Liat, Leung, Ling, Greenwald, Shirley, Azulay, Meir, Kumar, Sandeep, Alteber, Zoya, Pan, Xiaoyu, Machlenkin, Arthur, Benita, Yair, Drake, Andrew W., Chajut, Ayelet, Salomon, Ran, Vankin, Ilan, Safyon, Einav, Hunter, John, Levine, Zurit, White, Mark, Leidner, Rom, Kang, Hyunseok, Haddad, Robert, Segal, Neil H., Wirth, Lori J., Ferris, Robert L., Hodi, F. Stephen, Sanborn, Rachel E., Gajewski, Thomas F., Sharfman, William, McDonald, Dan, Srivastava, Shivani, Gu, Xuemin, Phillips, Penny, Passey, Chaitali, Seiwert, Tanguy, Habtetsion, Tsadik

Get full text

Sodium valproate stimulates potassium and chloride urinary excretion in rats: gender differences by Jakutiene, Eitaute, Grikiniene, Jurgita, Vaitkevicius, Arunas, Tschaika, Marina, Didziapetriene, Janina, Stakisaitis, Donatas

Get full text